Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)

References

• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. New Engl J Med 2003;349:583–96
   PubMed Web of Science ®Google Scholar
• Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006;75:333–66
   PubMed Web of Science ®Google Scholar
• Kelly JW. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr Opin Struct Biol 1998;8:101–6
   PubMed Web of Science ®Google Scholar
• Givens RC, Russo C, Green P, Maurer MS. Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medial center. Aging Health 2013;9:229–35
   PubMedGoogle Scholar
• Coelho T, Maia LF, Martins da Silva A, Cruz MW, Plante-Bordeneuve V, Lozeron P, Campistol JM, et al. Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial. Neurology 2012;79:785–92
   PubMed Web of Science ®Google Scholar
• Hammarstrom P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003;299:713–16
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins da Silva A, Cruz MW, Plante-Bordeneuve V, Suhr OB, Conceiçao I, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013;260:2802–14
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, et al. Repurposing diflunisal for familial amyloid polyneuropathy a randomized clinical trial. JAMA 2013;310:2658–67
   PubMed Web of Science ®Google Scholar
• Andrade CA. Peculiar form of peripheral neuropathy – familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952;75:408–27
   PubMed Web of Science ®Google Scholar
• Coelho T. Familial amyloid polyneuropathy: new developments in genetics and treatment. Curr Opin Neurol 1996;9:355–9
   PubMed Web of Science ®Google Scholar
• Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 2012;109:9629–34
   PubMed Web of Science ®Google Scholar
• Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 2012;421:185–203
   PubMed Web of Science ®Google Scholar
• Westermark P, Sletten K, Johansson B, Cornwell GG III. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990;87:2843–5
   PubMed Web of Science ®Google Scholar
• Mohammed SF, Mirzoyez SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014;2:113–22
   PubMed Web of Science ®Google Scholar
• Benson MD. Familial amyloidotic polyneuropathy. Trends Neurosci 1989;12:88–92
   PubMed Web of Science ®Google Scholar
• Falk RH. Cardiac amyloidosis a treatable disease, often overlooked. Circulation 2011;124:1079–85
   PubMed Web of Science ®Google Scholar
• Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. New Engl J Med 1997;336:466–73
   PubMed Web of Science ®Google Scholar
• Monaco HL, Rizzi M, Coda A. Structure of a complex of 2 plasma-proteins – transthyretin and retinol-binding protein. Science 1995;268:1039–41
   PubMed Web of Science ®Google Scholar
• Schreiber G, Richardson SJ. The evolution of gene expression, structure and function of transthyretin. Comp Biochem Phys B 1997;116:137–60
   PubMed Web of Science ®Google Scholar
• Blake CCF, Geisow MJ, Oatley SJ, Rerat B, Rerat C. Structure of pre-albumin – secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8-A. J Mol Biol 1978;121:339–56
   PubMed Web of Science ®Google Scholar
• Colon W, Kelly JW. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992;31:8654–60
   PubMed Web of Science ®Google Scholar
• Hurshman AR, White JT, Powers ET, Kelly JW. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 2004;43:7365–81
   PubMed Web of Science ®Google Scholar
• Babbes ARH, Powers ET, Kelly JW. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry 2008;47:6969–84
   PubMed Web of Science ®Google Scholar
• Wiseman RL, Johnson SM, Kelker MS, Foss T, Wilson IA, Kelly JW. Kinetic stabilization of an oligomeric protein by a single ligand binding event. J Am Chem Soc 2005;127:5540–51
   PubMed Web of Science ®Google Scholar
• Maurer MS, Grogan DR, Judge DP, Mundayat R, Packman J, Lombardo I, Quyyumi AA, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail 2015;8:519--26
   Google Scholar
• Rappley I, Monteiro C, Novais M, Baranczak A, Solis G, Wiseman RL, Helmke S, et al. Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry 2014;53:1993–2006
   PubMed Web of Science ®Google Scholar
• Wiseman RL, Green NS, Kelly JW. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis. Biochemistry 2005;44:9265–74
   PubMed Web of Science ®Google Scholar
• Oppenhei JH, Surks MI, Bernstein G, Smith JC. Metabolism of iodine-131-labeled thyroxine-binding prealbumin in man. Science 1965;149:748–50
   PubMed Web of Science ®Google Scholar
• Socolow EL, Woeber KA, Purdy RH, Holloway MT, Ingbar SH. Preparation of I131-labeled human serum prealbumin and its metabolism in normal and sick patients. J Clin Invest 1965;44:1600–9
   PubMed Web of Science ®Google Scholar
• Schneider F, Hammarstrom P, Kelly JW. Transthyretin slowly exchanges subunits under physiological conditions: a convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Sci 2001;10:1606–13
   PubMed Web of Science ®Google Scholar
• Keetch CA, Bromley EHC, McCammon MG, Wang N, Christodoulou J, Robinson CV. L55P transthyretin accelerates subunit exchange and leads to rapid formation of hybrid tetramers. J Biol Chem 2005;280:41667–74
   PubMed Web of Science ®Google Scholar
• Genereux JC, Qu S, Zhou M, Ryno LM, Wang S, Shoulders MD, Kaufman RJ, et al. Unfolded protein response-induced ERdj3 secretion links ER stress to extracellular proteostasis. EMBO J 2015;34:4–19
   PubMed Web of Science ®Google Scholar
• Shoulders MD, Ryno LM, Genereux JC, Moresco JJ, Tu PG, Wu C, Yates JR III, et al. Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep 2013;3:1279–92
   PubMed Web of Science ®Google Scholar